Form 4 for ABOS Acumen Pharmaceuticals, Inc.
Accepted 2026-06-10 16:51:13 ET · period of report 2026-06-09 · accession 0001628280-26-042280 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-10 16:51 | 2026-06-09 | ABOS | Fountain Nathan B | Dir | S - Sale | $2.23 | -6,400 | 48.1K | -12% | -$14.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-09 | S | D | 6,400 | $2.23 | 48,150 | D | — | — | (F1) The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $2.2300 to $2.2311. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |